Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 5/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SULT1E1 | P49888 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13455164 | 1.00 | CETP (0.56) | CETPPTPN1CDC25ADUSP3MAPKAPK2 | |
| SCHEMBL2230005 | 1.00 | CETP (0.56) | CETPPTPN1CDC25ADUSP3MAPKAPK2 | |
| SCHEMBL21858867 | 0.88 | CETP (0.59) | CETPPTPN1CDC25ADUSP3MAPKAPK2 | |
| SCHEMBL17394863 | 0.83 | CETP (0.56) | CETPPTPN1CDC25ADUSP3MAPKAPK2 | |
| SCHEMBL29934998 | 0.79 | CETP (0.46) | CETPPTPN1CDC25ADUSP3MAPKAPK2 | |
| SCHEMBL11937173 | 0.78 | CETP (0.54) | CETPPTPN1CDC25ADUSP3MAPKAPK2 | |
| SCHEMBL2229971 | 0.78 | CETP (0.54) | CETPPTPN1CDC25ADUSP3MAPKAPK2 | |
| SCHEMBL4604284 | 0.77 | PTPN1 (0.52) | CETPPTPN1CDC25ADUSP3MAPKAPK2 | |
| SCHEMBL4603951 | 0.74 | PTPN1 (0.46) | CETPPTPN1CDC25ADUSP3MAPKAPK2 | |
| SCHEMBL15874214 | 0.71 | PTPN1 (0.46) | CETPPTPN1CDC25ADUSP3MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658642-A1 | PROCESS FOR PREPARING A OXACYLOPENTANE DERIVATIVE | Firmenich SA (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20240327367-A1 | PROCESS FOR PREPARING A OXACYLOHEXANE OR OXACYLOPENTANE DERIVATIVE | FIRMENICH & CIE (CH) | 2024-10-03 | — | — | US | disclosed |
| WO-2024160930-A1 | PROCESS FOR PREPARING A OXACYLOPENTANE DERIVATIVE | FIRMENICH SA (CH) | 2024-08-08 | — | — | WO | disclosed |
| EP-4377301-A2 | PROCESS FOR PREPARING A OXACYLOHEXANE OR OXACYLOPENTANE DERIVATIVE | Firmenich SA (CH) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023006910-A2 | PROCESS FOR PREPARING A OXACYLOHEXANE OR OXACYLOPENTANE DERIVATIVE | FIRMENICH SA (CH) | 2023-02-02 | — | — | WO | disclosed |
| EP-2212306-B1 | PROCESS FOR THE PREPARATION OF TETRANORLABDANE DERIVATIVES | FIRMENICH & CIE (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-8227629-B2 | Process for the preparation of tetranorlabdane derivatives | FIRMENICH SA (CH) | 2012-07-24 | — | — | US | disclosed |
| US-8227630-B2 | Process for the preparation of tetranorlabdane derivatives | FIRMENICH SA (CH) | 2012-07-24 | — | — | US | disclosed |
| US-8227630-B2 | Process for the preparation of tetranorlabdane derivatives | FIRMENICH SA (CH) | 2012-07-24 | — | — | US | disclosed |
| US-20110218347-A1 | PROCESS FOR THE PREPARATION OF TETRANORLABDANE DERIVATIVES | FIRMENICH SA | 2011-09-08 | — | — | US | disclosed |
| US-20110218347-A1 | PROCESS FOR THE PREPARATION OF TETRANORLABDANE DERIVATIVES | FIRMENICH SA | 2011-09-08 | — | — | US | disclosed |
| EP-2215069-B1 | PROCESS FOR THE PREPARATION OF TETRANORLABDANE DERIVATIVES | FIRMENICH & CIE (CH) | 2011-07-06 | — | — | EP | disclosed |
| US-20100311990-A1 | PROCESS FOR THE PREPARATION OF TETRANORLABDANE DERIVATIVES | FIRMENICH SA (CH) | 2010-12-09 | — | — | US | disclosed |
| EP-1773799-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY-ACTIVE COMPOUNDS | GIVAUDAN SA (CH) | 2010-09-08 | — | — | EP | disclosed |
| US-7683190-B2 | Process for the preparation of optically-active compounds | GIVAUDAN SA (CH) | 2010-03-23 | — | — | US | disclosed |
| US-7683190-B2 | Process for the preparation of optically-active compounds | GIVAUDAN SA (CH) | 2010-03-23 | — | — | US | disclosed |
| WO-2009053884-A1 | PROCESS FOR THE PREPARATION OF TETRANORLABDANE DERIVATIVES | FIRMENICH SA (CH) | 2009-04-30 | — | — | WO | disclosed |
| US-20080064886-A1 | Process for the Preparation of Optically-Active Compounds | GIVAUDAN SA (CH) | 2008-03-13 | — | — | US | disclosed |
| US-20080064886-A1 | Process for the Preparation of Optically-Active Compounds | GIVAUDAN SA (CH) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218347-A1 | PROCESS FOR THE PREPARATION OF TETRANORLABDANE DERIVATIVES | CYP1B1, CYP11B1, CYP11B2 | CETP 2054/4885PTPN1 3468/4885CDC25A 2103/4885 |
| US-20240327367-A1 | PROCESS FOR PREPARING A OXACYLOHEXANE OR OXACYLOPENTANE DERIVATIVE | OSTC, CYP51A1, OXER1 | CETP 2827/4885PTPN1 3846/4885CDC25A 902/4885 |
| US-20080064886-A1 | Process for the Preparation of Optically-Active Compounds | ADH1C, ADH1A, CYP2E1 | CETP 2763/4885PTPN1 4562/4885CDC25A 1662/4885 |
| US-20100311990-A1 | PROCESS FOR THE PREPARATION OF TETRANORLABDANE DERIVATIVES | CYP1B1, CYP11B1, CYP11B2 | CETP 1742/4885PTPN1 3585/4885CDC25A 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.